このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Prospective Abuse and Intimate Partner Violence Surgical Evaluation (PRAISE-2)

2018年6月25日 更新者：McMaster University

Prospective Abuse and Intimate Partner Violence Surgical Evaluation (PRAISE-2) : A Multicentre Pilot Prospective Cohort Study

Intimate partner violence (IPV), also known as domestic abuse, is a leading cause of non-fatal injury in women worldwide. 1 in 6 women attending surgical fracture clinics have a history of IPV in the past year. Given the high prevalence and costs associated with IPV, there is a need to identify health outcomes associated with IPV, the incidence of new and worsening cases of IPV, and resource use among IPV victims. This prospective cohort study of women with fractures and dislocations will assess differences in injury-related outcomes (time to fracture healing, injury-related complications, and return to pre-injury function) between abused and non-abused women. This study will also determine whether a musculoskeletal injury can lead to new or worsening abuse by an intimate partner and how patterns of IPV change over time following musculoskeletal injuries.Finally, the proposed study will also inform the feasibility of a larger multinational cohort study.

調査の概要

状態

わからない

条件

介入・治療

詳細な説明

Number of Participants:

250

Primary Research Objectives:

Feasibility

Secondary Research Objective:

The secondary objectives are to determine:

  1. How a history of IPV affects injury-related complications;
  2. How a history of IPV affects return to pre-injury function;
  3. Incident cases of IPV after a musculoskeletal injury, if the injury was not the result of IPV;
  4. How a history of IPV affects health care and support service use after a musculoskeletal injury;
  5. How a history of IPV affects health-related quality of life after a musculoskeletal injury;
  6. How patterns of IPV change over time after a musculoskeletal injury;
  7. How abused women's stage of change changes over time after a musculoskeletal injury

Diagnosis and Main Inclusion Criteria:

The inclusion criteria are:

  1. adult females (at least 16 or 18 years of age depending on local ethics requirements);
  2. patients presenting to participating fracture clinics within 6 weeks of their musculoskeletal injury;
  3. patients presenting with a fracture or dislocation which is being managed with either surgical or non-surgical treatment.

The exclusion criteria are:

  1. unwilling to or unable to provide consent;
  2. unable to complete the study questionnaires in a private location, due to safety and confidentiality;
  3. unwilling or unable to follow the study protocol or their attending surgeon has concerns about their ability or willingness to follow study protocols;
  4. does not speak and write in English or the dominant language of the local clinic

Study Outcomes:

The primary outcome is feasibility. Secondary outcomes are injury-related complications, return to function, incidence of IPV, quality of life, abuse type and severity, and stage of change.

Duration of Patient Follow-Up:

Study participants will be followed for 12 months

研究の種類

観察的

入学 (実際)

250

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • カナダ
    • Ontario
      • Hamilton、Ontario、カナダ、L8R 3H6
        • McMaster University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

16年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

サンプリング方法

非確率サンプル

調査対象母集団

Adult women presenting to participating fracture clinics with a fracture or dislocation.

説明

Inclusion Criteria:

  • Adult females
  • Patients presenting to participating fracture clinics within 6 weeks of their musculoskeletal injury
  • Patients presenting with a fracture or dislocation which is being managed with either surgical or non-surgical treatment

Exclusion Criteria:

  • Unwilling to or unable to provide consent
  • Unable to complete the study questionnaires in a private location
  • Unwilling or unable to follow the study protocol or their attending surgeon has concerns about their ability or willingness to follow study protocols
  • Does not speak and write in English or the dominant language of the local clinic

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Experienced abuse
Experienced IPV in the past 12 months
他の：標準治療
Did not experience abuse
Did not experience IPV in the past 12 months.
他の：標準治療

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Feasibility - Recruitment rate
時間枠：12 months
Number of patients recruited at each site during a 12 month period
12 months
Feasibility - Proportion of Missed and/or out of window visits
時間枠：12 months
Proportion of missed and out of window visits
12 months
Feasibility - Collection of secondary outcomes (Proportion of included patients followed at 12 months for the primary and secondary outcomes)
時間枠：12 months
Proportion of included patients followed at 12 months for the primary and secondary outcomes
12 months
Feasibility - Completion of data collection (proportion of case report forms, including patient questionnaires, completed at 12 months)
時間枠：12 months
The proportion of case report forms, including patient questionnaires, completed at 12 months.
12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of patients with injury-related complications assessed by central adjudication
時間枠：12 months
Compare proportion of patients experiencing a composite of injury-related complications between patients who self-report a history of IPV and those who do not. Injury-related complications include non-union, malunion, infection, unplanned secondary procedure, mortality, hardware failure, etc. An independent, blinded adjudicator will determine whether the event is injury-related.
12 months
Return to function questionnaire
時間枠：12 months
We will use the Return to Function Questionnaire (RTF) to compare the mean time to return to pre-injury function among women who disclose a history of IPV versus those who do not disclose IPV. The RTF is a 4 question tool that was used in a recently completed large FDA-regulated fracture trial.
12 months
IPV incidence questionnaire
時間枠：12 months
Women's self-reported experience of IPV will be measured using a direct method of screening used by the PRAISE Investigators in 2 previous studies conducted in trauma populations. A participant will be considered to have disclosed IPV if she answers positively to at least 1 of the 3 direct screening questions.
12 months
Resource use questionnaire
時間枠：12 months
Women's access to and use of health and support services will be measured by directly asking participants to self-report if they have accessed health care services, a social worker, mental health professional, women's shelter, helpline, violence against women website, or legal assistance.
12 months
Quality of life - EQ-5D
時間枠：12 months
Participants' quality of life will be measured using the EuroQol-5 Dimensions (EQ-5D), a widely used and well-validated quality of life tool. The EQ-5D is a comprehensive, 5-item compact health status classification and health state preference questionnaire.
12 months
IPV frequency questionnaire
時間枠：12 months
Using 3 questions from the Woman Abuse Screening Tool, which categorizes frequency of different types of violence, we will record and analyze changes in frequency of IPV experienced over time.
12 months
Stage of change questionnaire
時間枠：12 months
Participants will complete the Domestic Violence Survivor Assessment (DVSA) Short Form questionnaire to determine her stage of change. The stages of change are based on the transtheoretical model of health behavior change applied specifically to survivors of abuse. We developed the DVSA Short Form for the purpose of this study, with the aim of making the self-administered form more accessible.
12 months
IPV type questionnaire
時間枠：12 months
Using 3 questions from the Woman Abuse Screening Tool, which categorizes types of violence as physical, emotional, and/or sexual abuse, we will record and analyze changes in type of IPV experienced over time.
12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

McMaster University

協力者

Canadian Institutes of Health Research (CIHR)
The Physicians' Services Incorporated Foundation

捜査官

  • 主任研究者：Brad Petrisor, MD, MSc、Hamilton Health Sciences Corporation

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2015年8月1日

一次修了 (予想される)

2019年6月1日

研究の完了 (予想される)

2019年6月1日

試験登録日

最初に提出

2015年8月7日

QC基準を満たした最初の提出物

2015年8月19日

最初の投稿 (見積もり)

2015年8月20日

学習記録の更新

投稿された最後の更新 (実際)

2018年6月26日

QC基準を満たした最後の更新が送信されました

2018年6月25日

最終確認日

2018年6月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • PRAISE-2

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する